Menu
Fechar
hrs4r
 I want to donate

The Precision Oncology research group in Girona (OncoGiR_Pro) is made up of researchers who are members of the ICO Girona Medical Oncology Service and collaborators from other services, located at the Hospital Dr. Josep Trueta. Led by Dr. Joaquim Bosch, the research group's mission is to integrate clinical, epidemiological and translational research in the field of precision oncology. The aim is to develop new therapeutic strategies and identify biomarkers for predicting the risk and clinical course of various cancers.

Main lines of research
  • Clinical development of new drugs, biomarkers for predicting response to treatment and clinical evolution, genetic basis of hereditary cancer, cancer risk prediction models.

These lines of research apply to different tumours: breast, digestive, thoracic, urological, skin, ENT and gynaecological.

Strategic objectives
  • Mission: To integrate clinical, epidemiological and translational research in the field of precision oncology.
  • Goal: To develop new therapeutic strategies and identify biomarkers for the prediction of risk and clinical evolution of different cancers.
Publications
Tavira B, Iscar T, Manso L, Santaballa A, Gil-Martin M, García García Y, Romeo M, Iglesias M, de Juan Ferré A, Barretina-Ginesta MP, Manzano A, Gaba L, Rubio MJ, de Andrea CE, González-Martín A

Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

CLINICAL CANCER RESEARCH, 2024, 30, 176-186 dx.doi.org/10.1158/1078-0432.CCR-23-0771
Fernández-Castillejo S, Roig B, Melé M, Serrano S, Salvat M, Querol M, Brunet J, Pineda M, Cisneros A, Parada D, Badia J, Borràs J, Rodríguez-Balada M, Gumà J

Opportunistic genetic screening increases the diagnostic yield and is medically valuable for care of patients and their relatives with hereditary cancer

JOURNAL OF MEDICAL GENETICS, 2024, 61, 69-77 dx.doi.org/10.1136/jmg-2023-109389
Gonzalez-Abuin N, Pons T, Fuster T, Quintana I, Terradas M, Aiza G, Brunet J, Capellá G, Hampel H, Valle L

Lack of evidence for germline <i>WWP1</i> pathogenic variants in gastrointestinal polyposis and other phenotypes suggestive of PTEN-hamartoma-tumor syndrome

GENES & DISEASES, 2024, 11, 524-527 dx.doi.org/10.1016/j.gendis.2023.03.011
Mostaghim A, Minkove S, Aguilar-Company J, Ruiz-Camps I, Eremiev-Eremiev S, Dettorre GM, Fox L, Tondini C, Brunet J, Carmona-García M, Lambertini M, Bower M, Newsom-Davis T, Sharkey R, Pria AD, Rossi M, Plaja A, Salazar R, Sureda A, Prat A, Michalarea V, Van Hemelrijck M, Sita-Lumsden A, Bertuzzi A, Rimassa L, Rossi S, Rizzo G, Pedrazzoli P, Lee AJ, Murphy C, Belessiotis K, Diamantis N, Mukherjee U, Pommeret F, Stoclin A, Martinez-Vila C, Bruna R, Gaidano G, D'Avanzo F, Gennari A, Athale J, Eichacker P, Pinato DJ, Torabi-Parizi P, Cortellini A, OnCovid study group.

Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2024, 139, 13-20 dx.doi.org/10.1016/j.ijid.2023.11.021
Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Prelaj A, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar Nana F, Ponce S, Albarrán-Artahona V, Dal Maso A, Spotti M, Mielgo X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier JB, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Mezquita L, Planchard D

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.

CLINICAL LUNG CANCER, 2024, 25 dx.doi.org/10.1016/j.cllc.2023.11.007
Candal-Pedreira C, Ruano-Ravina A, Calvo de Juan V, Cobo M, Trigo JM, Rodríguez-Abreu D, Estival A, Carcereny E, Cucurull M, López Castro R, Medina A, García Campelo R, Cordeiro González P, Sánchez-Gastaldo A, Bosch-Barrera J, Massutí B, Dómine M, Camps C, Ortega AL, Sánchez-Hernández A, Guirado Risueño M, Del Barco Morillo E, Garrido Fernández A, Provencio M

Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

ARCHIVOS DE BRONCONEUMOLOGIA, 2024, 60, 88-94 dx.doi.org/10.1016/j.arbres.2023.12.005
Vincenzi B, Cortellini A, Mazzocca A, Orlando S, Romandini D, Aguilar-Company J, Ruiz-Camps I, Valverde Morales C, Eremiev-Eremiev S, Tondini C, Brunet J, Bertulli R, Provenzano S, Bower M, Generali D, Salazar R, Sureda A, Prat A, Vasiliki M, Van Hemelrijck M, Sita-Lumsden A, Bertuzzi A, Rossi S, Jackson A, Grosso F, Lee AJX, Murphy C, Belessiotis K, Mukherjee U, Pommeret F, Loizidou A, Gaidano G, Dettorre GM, Grisanti S, Tucci M, Fulgenzi CAM, Gennari A, Napolitano A, Pinato DJ

Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16 dx.doi.org/10.1177/17588359231225028
Pardo-Cea MA, Farré X, Esteve A, Palade J, Espín R, Mateo F, Alsop E, Alorda M, Blay N, Baiges A, Shabbir A, Comellas F, Gómez A, Arnan M, Teulé A, Salinas M, Berrocal L, Brunet J, Rofes P, Lázaro C, Conesa M, Rojas JJ, Velten L, Fendler W, Smyczynska U, Chowdhury D, Zeng Y, He HH, Li R, Van Keuren-Jensen K, de Cid R, Pujana MA

Biological basis of extensive pleiotropy between blood traits and cancer risk

GENOME MEDICINE, 2024, 16, 21-21 dx.doi.org/10.1186/s13073-024-01294-8
Fortuno C, Feng BJ, Carroll C, Innella G, Kohlmann W, Lázaro C, Brunet J, Feliubadaló L, Iglesias S, Menéndez M, Teulé A, Ballinger ML, Thomas DM, Campbell A, Field M, Harris M, Kirk J, Pachter N, Poplawski N, Susman R, Tucker K, Wallis M, Williams R, Cops E, Goldgar D, kConFab Investigators, James PA, Spurdle AB

Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum.

JCO Precision Oncology, 2024, 8, 2300453-2300453 dx.doi.org/10.1200/PO.23.00453
Rodriguez-Abreu D, Bosch-Barrera J, Gray JE, Ahn MJ, Johnson M, Yu X, Mohammad S, Chen X, Todd T, Kim J, Reck M

STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations

CLINICAL LUNG CANCER, 2024, 25, 274-279 dx.doi.org/10.1016/j.cllc.2023.12.010
Competitive projects
Precision Oncology in Girona

CarboSign7 for cancer diagnosis: Biosampling optimization and validation for gastric and lung cancer

Codi oficial: CI23-20369 Start date:30/10/2023 Data fi: 30/10/2025 Investigador/a principal: ADELAIDA GARCIA VELASCO Organisme finançador: FUNDACIÓN BANCARIA LA CAIXA
Precision Oncology in Girona

Avaluació del grau de resposta patològica tumoral al tractament amb inhibidors de l’angiogènesi i del factor de creixement epidèrmic, en combinació a quimioteràpia, de les metàstasi hepàtiques de càncer colorectal ressecades

Codi oficial: VEGF/EGFR Start date:11/06/2022 Data fi: 17/10/2024 Investigador/a principal: XAVIER HERNÁNDEZ YAGÜE Organisme finançador: FUNDACIÓ ACADÈMIA CIÈNCIES MÈDIQUES
Precision Oncology in Girona

CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE

Codi oficial: 101095483 Start date:01/01/2023 Data fi: 31/12/2025 Investigador/a principal: JOAN BRUNET VIDAL Organisme finançador: EUROPEAN COMISSION
Precision Oncology in Girona

Evaluación de un nuevo biomarcador pan-cáncer para mejorar la predicción de respuesta a inmunoterapia.

Codi oficial: biomarcador pan-cáncer Start date:19/10/2020 Data fi: 01/12/2025 Investigador/a principal: JOAN BRUNET VIDAL Organisme finançador: SOCIEDAD ESPAÑOLA DE ONCOLOGÍA MÉDICA (SEOM)
Precision Oncology in Girona

Validación de la utilidad clínica de la evaluación de la inestabilidad de microsatélites con alta sensibilidad en la mejora del diagnóstico precoz de cáncer de endometrio y en el establecimiento de estrategias de seguimiento ginecológico personalizadas en síndrome de Lynch (PROJECTES)

Codi oficial: Inestabilidad de microsatélites con alta sensibilidad Start date:01/05/2023 Data fi: 27/04/2025 Investigador/a principal: JOAN BRUNET VIDAL Organisme finançador: SOCIEDAD ESPAÑOLA DE ONCOLOGÍA MÉDICA (SEOM)
Precision Oncology in Girona

A therapeutic strategy to co-target brain metastasis-initiating and hyperlipidemia-driving mechanisms in lorlatinib-treated NSCLC

Codi oficial: Pfizer 2019 Joaquim Bosch Start date:05/07/2019 Data fi: 31/12/2024 Investigador/a principal: JOAQUIM BOSCH BARRERA, JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: PFIZER, S.L.U.
Precision Oncology in Girona

TalentGi_RFort_despesa_2024

Codi oficial: TalentGi_RFort_despesa_2024 Start date:21/06/2024 Data fi: 31/10/2024 Investigador/a principal: JOAQUIM BOSCH BARRERA, ROSER FORT CULILLAS
Job offers

Team

If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in

About IDIBGI!

 menu